Eric Halioua is a serial entrepreneur with strong managerial, technological, fund-raising and deal-making experience. Eric Halioua is President and CEO of PDC*line Pharma a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic cells (PDC*line). He is as well Board member of the biotechnology company Bioxodes (Belgium), HairClone (UK), VitriCell (Belgium) and member of the strategic advisory board of Innobiochips (France). He has raised more than €90 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy.
Eric is co-founder of four biotechnology called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. Eric worked for 12 years as a Principal in the Healthcare and Life Sciences Practice of Arthur D. Little where he led work in the areas of strategy, M&A and technology & innovation management. He also worked as project leader in the corporate R&D centre of Astra-Zeneca. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.